Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program

Li, Hui; Zong, Zhen; Zhou, Taicheng; Sun, Lina; Wang, Anan; Zhang, Kun‐He; Yi, Chenghao

doi:10.21037/jgo.2019.06.07

Cited by 19 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SRCC of the pancreas is extremely rare and has a very poor prognosis [3]. According to the study using the Surveillance, Epidemiology, and End Results database from 2000 to 2014, the incidence of pancreatic SRCC is 0.4-0.5% among all cases of pancreatic carcinoma [1]. Among the eight cases reported thus far (Table 1) [4][5][6][7][8][9][10][11], surgical treatment with radical resection, pancreatoduodenectomy, and/or total pancreatomy could be performed in four cases, and there was only one case of borderline-resectable tumor treated with neoadjuvant chemotherapy with gemcitabine.…”

Section: Discussionmentioning

confidence: 99%

“…Two studies have reported on the prognosis of patients with pancreatic SRCC. In the rst, where the prognosis was investigated according to the tumor location (esophagus, stomach, small intestine, appendix, colon, and rectum), the group with pancreatic SRCC had the worst median overall survival (3.4 months) [1]. The second study evaluated the predictive effects of epidemiological factors and treatment interventions on the overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…We performed adjuvant chemotherapy with S-1, which is an oral uoropyrimidine that contains tegafur, a prodrug of 5-uorouracil, gimeracil, and oteracil potassium. The e cacy of S-1 for improving the postoperative survival has been reported in gastric cancer [12], which has the highest incidence of SRCC among gastroenterological tumors [1], and pancreatic cancer [13]. According to the Japanese guidelines, adjuvant chemotherapy with S-1 is recommended for gastric and pancreatic cancer [14][15].…”

Section: Discussionmentioning

confidence: 99%

“…Signet ring cell carcinoma (SRCC) of the pancreas is extremely rare, representing < 1% of pancreatic cancers [1]. The prognosis of this tumor has been reported to be very poor [2].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

Takagi

Tokuda

Tanaka

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Signet ring cell carcinoma (SRCC) of the pancreas is a very rare histologic variant of pancreatic carcinoma with very poor prognosis. We present a case of pancreatic SRCC with good prognosis achieved by resection and adjuvant chemotherapy with S-1 one year, which is the standard treatment for advanced resected gastric cancer in Japan. The stomach carried a higher incidence of SRCC than other sites.Case presentation: A 70-year-old man presented with abdominal discomfort, and ultrasonography revealed a mass in the pancreas. Computed tomography showed a hypovascular tumor in the head of the pancreas, 51 mm in diameter, with invasion to the portal vein and duodenum. The patient underwent pancreaticoduodenectomy (PD) with portal vein resection and reconstruction. The pathological diagnosis was SRCC of the pancreas without invasion to the portal vein, pT3N1M0 Stage IIB (UICC classification). Subsequently, postoperative adjuvant chemotherapy with S-1 was initiated to prevent recurrence. The patient has remained recurrence-free for 2 years and 6 months after PD. Conclusion: Adjuvant chemotherapy with S-1 may be an important factor for improving the prognosis of patients with resectable SRCC of the pancreas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Signet ring cell carcinoma (SRCC) of the pancreas is extremely rare, representing < 1% of pancreatic cancers [1]. The prognosis of this tumor has been reported to be very poor [2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

Takagi

Tokuda

Tanaka

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Another analysis [29] focused on trends of incidence and predictors affect the overall survival of patients with SRC in gastrointestinal tract and pancreas. Nowadays, no study has focused on the signi cance of lymph node ratio and total number of lymph nodes examined of pancreatic SRCC.…”

Section: Discussionmentioning

confidence: 99%

The value of lymph node ratio and total number of lymph nodes examined for resected pancreatic signet ring cell carcinoma: a retrospective cohort study

Ren¹,

Xue²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background—Pancreatic signet ring cell carcinoma (SRCC) was an exceedingly rare histological subtype of pancreatic cancer. Previous studies focused on the trends of incidence and independent predictors of pancreatic SRCC. Our objectives of the study was to analyze the prognostic value of lymph node ratio (LNR) and explore the minimal number of lymph nodes examined to accurately evaluate the N stage in resected pancreatic signet ring cell carcinoma.Method—The data diagnosed from January 1, 1990 to December 31, 2016 constituted the study cohort from the Surveillance, Epidemiology, and End Results(SEER) registry. We calculated overall survival (OS) of these patients using Kaplan–Meier analysis and Cox proportional hazards model and used receiver-operating characteristic curve (ROC) analysis to investigate the discriminatory ability of the total number of lymph nodes examined(TNLE) relative to whether lymph node metastasis.Results—The median number of lymph nodes examined among 120 patients of resected pancreatic SRCC was 14 (interquartile range, 6.25 to 20.0).According to the univariate analysis of overall survival(OS) result, age, grade, chemotherapy, LNR and TNLE were significantly different(P<0.05).Multivariate survival analysis showed that LNR and grade were the independent prognostic indicators after pancreatic SRCC resection for OS. TNLE ≥ 8 showed the highest discriminatory power to evaluate whether the lymph node metastasis (AUC 0.656, 95%CI 0.564-0.741, Youden index 0.2533, sensitivity 78.67%, specificity 46.67%, P= 0.003)Conclusion—Our study indicated that LNR was a valuable independent prognostic factor for resected pancreatic SRCC. Regional lymphadenectomy of at least 8 lymph nodes was necessary to stage patients accurately. Enough number lymph nodes examined was necessary for the clinicians to accurately predict the significance of LNR in resected pancreatic SRCC.

show abstract

Signet Ring Cell Gastric Carcinoma: Clinical Epidemiology and Outcomes in a Predominantly Latino County Hospital Population

Fung

Patel

et al. 2020

Dig Dis Sci

View full text Add to dashboard Cite

Background Gastric signet ring cell carcinoma (GSRC) is a rare but increasingly prevalent tumor histotype whose clinical features and natural history are poorly understood, particularly in the USA and minorities. Aims To examine the occurrence, clinico-demographic characteristics, oncologic features, treatment, and outcomes of GSRC in a predominantly minority county hospital setting and benchmark them against data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Methods We queried biopsy-proven GSRC cases at a Los Angeles County hospital, from 2004 to 2017. Clinical characteristics, treatment, and survival data were collected and compared to SEER data. Results We identified 63 patients with GSRC. Compared to SEER, our cohort was significantly younger (52.6 vs. 63.5 years, p < 0.01), Hispanic/Latino predominant (81% vs. 20%, p < 0.01), had higher overall stage (86% vs. 69% with stage III/IV, p < 0.01), and more frequent node involvement (89% vs. 49%, p < 0.01). Lower tumor stage, Helicobacter pylori positivity, and surgical intervention were associated with significantly longer median survival (all p < 0.05), which was similar in our study compared to SEER (median 12.6 vs. 9.0 months, p = 0.26). Conclusions Patients with GSRC within the Los Angeles County population have different clinical characteristics compared to what has been reported in SEER. Our cohort was younger, and despite having more advanced disease, did not have shorter survival. Further study is needed to better identify protective and risk factors in this population and improve understanding of the etiopathogenesis and natural history of this malignancy.

show abstract

Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program

Cited by 19 publications

References 27 publications

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

The value of lymph node ratio and total number of lymph nodes examined for resected pancreatic signet ring cell carcinoma: a retrospective cohort study

Signet Ring Cell Gastric Carcinoma: Clinical Epidemiology and Outcomes in a Predominantly Latino County Hospital Population

Contact Info

Product

Resources

About